RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of “Reduce” by Analysts

Posted by on Jun 7th, 2026

Shares of RxSight, Inc. (NASDAQ:RXST – Get Free Report) have earned an average rating of “Reduce” from the fifteen brokerages that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $9.4444.

RXST has been the subject of a number of analyst reports. Piper Sandler reduced their price objective on shares of RxSight from $11.00 to $10.00 and set a “neutral” rating for the company in a research note on Thursday, February 26th. Stifel Nicolaus reduced their price objective on shares of RxSight from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Monday, March 9th. UBS Group raised their target price on RxSight from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Thursday, February 26th. Needham & Company LLC decreased their target price on RxSight from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Wells Fargo & Company decreased their target price on RxSight from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Thursday, May 7th.

Read Our Latest Research Report on RXST

Institutional Trading of RxSight

Several hedge funds and other institutional investors have recently modified their holdings of RXST. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of RxSight by 6.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,861 shares of the company’s stock worth $552,000 after buying an additional 1,232 shares during the period. Goldman Sachs Group Inc. grew its position in RxSight by 57.9% during the first quarter. Goldman Sachs Group Inc. now owns 310,411 shares of the company’s stock valued at $7,838,000 after purchasing an additional 113,767 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in RxSight by 9.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 93,382 shares of the company’s stock valued at $2,358,000 after purchasing an additional 8,424 shares in the last quarter. Creative Planning purchased a new position in RxSight during the second quarter valued at approximately $207,000. Finally, Legal & General Group Plc grew its position in RxSight by 5.0% during the second quarter. Legal & General Group Plc now owns 44,574 shares of the company’s stock valued at $579,000 after purchasing an additional 2,121 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Trading Down 2.0%

RXST stock opened at $5.00 on Friday. RxSight has a one year low of $4.70 and a one year high of $16.00. The firm has a market capitalization of $207 million, a PE ratio of -4.42 and a beta of 1.14. The firm has a 50-day moving average of $6.37 and a two-hundred day moving average of $8.44.

About RxSight

(Get Free Report)

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.

Featured Articles

Analyst Recommendations for RxSight (NASDAQ:RXST)

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.